Oramed initiated with an Overweight at Cantor Fitzgerald 07:11 ORMP Might be time to look at DraftKing again. It was a big loser for me because I had alarge amount-- so sure was I---I probably bought at $50+!-> I sold a long time ago in the $40's. Now post super bowl, Post NY betting and post earn let the dust settle and put some away- this company is not going bankrupt.
CPRT @$124 Copart price target lowered to $160 from $170 at Baird 07:08 CPRT Baird analyst Craig Kennison lowered the firm's price target on Copart to $160 from $170 and keeps an Outperform rating on the shares. The analyst said the business is as strong as ever, as the company gains share and expands its service globally, but the market has begun to account for his "peak-RPU, peak-margin" scenario.
<<<<<<YMR- Your Morning Review>>>>>> DraftKings raises 2022 revenue view $1.85B-$2B from $1.7B-$1.9B, consensus $1.9B 07:04 DKNG DraftKings is also introducing fiscal year 2022 Adjusted EBITDA guidance. The Company expects its Adjusted EBITDA loss in 2022 to be between $825 million and $925 million. DraftKings reports Q4 revenue $473M, consensus $445.3M 07:03 DKNG Monthly Unique Payers for the B2C segment increased 32% compared to the fourth quarter of 2020. On average, 2M monthly unique paying customers engaged with DraftKings during each month of the fourth quarter. Average Revenue per MUP was $77 in the fourth quarter of 2021 representing a 19% increase versus the same period in 2020. "DraftKings' strong fourth quarter performance exceeded our expectations on the top and bottom line," said Jason Robins, DraftKings' co-founder, Chief Executive Officer and Chairman of the Board. "Our excellent quarter capped off a year in which five of our states were Contribution Profit positive, further demonstrating the effectiveness of our state playbook and supporting our positive view of the industry's TAM. We enter 2022 positioned to grow our market share, further optimize our user experience and continue to strengthen our multi-product suite of offerings." Bloomin' Brands reports Q4 adjusted EPS 60c, consensus 52c 07:03 BLMN Chuy's price target raised to $31 from $28 at Baird 06:59 CHUY Corsair Gaming to replace First Midwest in S&P 600 at open on 2/18 04:55 CRSR, FMBI Golden Entertainment price target raised to $66 from $64 at Macquarie 04:52 GDEN Cathie Wood's ARK Investment bought 35K shares of Teradyne today 20:21 TER OMG She finally made a good buy! Blue Water 2.22M share IPO priced at $9.00 19:26 BWV The deal priced at midpoint of its $8.00-$10.00 range. Maxim is acting as sole book running manager for the offering. Dropbox sees FY22 revenue $2.32B-$2.33B, consensus $2.36B 17:34 DBX Sees FY22 gross margin 81%. Sees FY22 operating margin 29%. Sees FY22 free cash flow $760M-$790M. Sees FY22 cash capital expenditures $25M-$35M. Dropbox sees long-term gross margin 80%-82% 16:57 DBX Sees long-term operating margin 30%-32%. Says has significant revenue and cash flow scale. Guidance taken from Q4 investor presentation slides. Celanese near deal to buy DuPont materials unit for over $10B, Bloomberg says ยป 17:08 CE, DD RBC Capital starts Verve Therapeutics at Outperform on 'disruptive' treatment 17:02 VERV RBC Capital analyst Luca Issi initiated coverage of Verve Therapeutics with an Outperform rating and $42 price target. The company is poised to disrupt current standard of care for heart disease by permanently silencing genes with a one-and-done approach, the analyst tells investors in a research note. Issi adds that while the irreversible nature of the intervention will give some people pause, he is positive on its validated targets, proven delivery, and safe editing. Taysha Gene Therapies initiated with an Outperform at SMBC Nikko 16:38 TSHA SMBC Nikko initiated coverage of Taysha Gene Therapies with an Outperform rating and $25 price target. Show Related Items >> Stifel expects further upside for Star Bulk Carriers after 'strong quarter' 15:24 SBLK Stifel analyst Benjamin Nolan said Star Bulk Carriers reported a "strong quarter" driven by higher charter rates, declared a "much better than expected" $2.00 dividend to be paid in Q1, and gave "fantastic rate guidance" for Q1. Given that he is modeling dividends of $5.25 for the full year, including the $2.00 dividend to be paid in Q1, and he views the dry bulk market as "still very firm," Nolan still expects further upside and maintains a Buy rating and $35 price target on Star Bulk shares. CoPart Am I diversified?- 2:16 mark
God No I have NO idea what Roku does and have never ever seen one of their units anywhere this may be a fake company.. Vaguely remember a stick you plugged into your TV?
--- Wow. This was an unfortunate post. You can see investing in this market is no easy task. There are eleven ideas here and not a one of them worked. I like to look through these posts to make sure we have the right level of quality control. So ABB is still there the rest is absolutely fallen apart. So DKNG That's The One. It's under $35. Van should we add DKNG & ABB? CPRT?